New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Subscribe To Our Newsletter & Stay Updated
